

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 9,388,134 B2
APPLICATION NO. : 14/311788
DATED : July 12, 2016
INVENTOR(S) : Lili Feng et al.

Page 1 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification

Column 11:

Lines 20-22, "(2R,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester"

Should read:

--(2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester--.

Column 12:

Lines 21-22, "5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester"

Should read:

--5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester--;

Lines 23-24, "5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid"

Should read:

--5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid--; and

Lines 43-45, "(2R,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester"

Should read:

--(2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester--.

Column 14:

Lines 24-25, "(2R,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester"

Should read:


--(2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester--; and

Lines 65-66, "[valsartan((2R,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester)]Na₃.xH₂O"

Should read:

--[3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'ylmethyl} amino)butyrate]Na₃ • xH₂O--.

Signed and Sealed this
Twenty-ninth Day of October, 2019



Andrei Iancu
Director of the United States Patent and Trademark Office